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ATP2C1, encoding the human secretory pathway Ca2þ -ATPase (hSPCA1), was recently identiﬁed as the defective
gene in Hailey–Hailey disease (HHD), an autosomal dominant skin disorder characterized by abnormal keratinocyte
adhesion in the suprabasal layers of the epidermis. In this study, we used denaturing high-performance liquid
chromatography to screen all 28 exons and ﬂanking intron boundaries of ATP2C1 for mutations in 9 HHD patients.
Nine different mutations were identiﬁed. Five of these mutations, including one nonsense, one deletion, two splice-
site, and one missense mutation, have not been previously reported. Recently, functional analysis of a series of
site-speciﬁc mutants, designed to mimic missense mutations found in ATP2C1, uncovered speciﬁc defects in Ca2þ
and/or Mn2þ transport and protein expression in mutant hSPCA1 polypeptides. In order to investigate the
molecular and physiological basis of HHD in the patient carrying missense mutation A528P, located in the putative
nucleotide binding domain of the molecule, site-directed mutagenesis was employed to introduce this mutation
into the wild-type ATP2C1 (hSPCA1) sequence. Functional analyses of HHD-mutant A528P demonstrated a low level
of protein expression, despite normal levels of mRNA and correct targeting to the Golgi, suggesting instability or
abnormal folding of the mutated hSPCA1 polypeptides. Analogous to conclusions drawn from our previous
studies, these results further support the theory of haploinsufﬁciency as a prevalent mechanism for the dominant
inheritance of HHD, by suggesting that the level of hSPCA1 in epidermal cells is critical.
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Hailey–Hailey disease (HHD, OMIM 16960), otherwise
known as familial benign chronic pemphigus, is an auto-
somal dominant skin disorder that typically manifests as
uncomfortable erosions or lesions in flexures or at sites of
trauma. The disorder, which usually presents in the third or
fourth decade, is histologically characterized by loss of
cohesion between suprabasal keratinocytes (acantholysis)
and dyskeratosis of the epidermis (Lever and Schaumburg-
Lever, 1983). Ultrastructural studies have revealed a break-
down of the desmosome–keratin filament complex (Wilgram
et al, 1962; Gottlieb and Lutzner, 1970; Ishibashi et al, 1984;
Kowalewski et al, 2001). HHD displays much similarity, both
clinically and histologically, to Darier’s disease (DD), another
dominantly inherited dermatosis. Recently, the importance
of Ca2þ in maintaining epidermal integrity was highlighted
by the identification of ATP2A2, encoding the sarco(endo)-
plasmic reticulum Ca2þ -transport ATPase (SERCA2), as the
defective gene in DD (Sakuntabhai et al, 1999). This was
closely followed by ATP2C1, encoding the related human
secretory pathway Ca2þ /Mn2þ ATPase (hSPCA1), being
identified as the defective gene in HHD (Hu et al, 2000;
Sudbrak et al, 2000). A spectrum of missense, frameshift,
splice-site, and nonsense mutations have since been
reported in ATP2C1 (Ikeda et al, 2001; Chao et al, 2002;
Dobson-Stone et al, 2002; Yokota et al, 2002). Comparison
between genotype and phenotype failed to yield any clear
correlation between the nature of the mutation and the
clinical features of HHD (Ikeda et al, 2001; Dobson-Stone
et al, 2002).
To date, the best-characterized member of the secretory
pathway Ca2þ /Mn2þ ATPase (SPCA) class is the Sacchar-
omyces cerevisiae homologue, named somewhat confus-
ingly PMR1 for plasma membrane ATPase-related. Following
its identification as a probable Ca2þ /Mn2þ ATPase (Rudolf
et al, 1989; Lapinskas et al, 1995), the protein was localized
to the Golgi compartment (Antebi and Fink, 1992). Null
yeast strains defective in PMR1 illustrated a pleiotropic
Abbreviations: DD, Darier’s disease; DHPLC, denaturing high
performance liquid chromatography; HHD, Hailey–Hailey disease;
(h)SPCA1, (human) secretory pathway Ca2þ /Mn2þ ATPase; nt,
nucleotide; PMR1, plasma membrane ATPase-related; PTC, pre-
mature termination codon; SERCA, sarco(endo)plasmic reticulum
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effect on Golgi function including impaired proteolytic
processing, incomplete glycosylation, and abnormal pre-,
post- and intra-Golgi translocation of secreted proteins.
These defects resulted in defective cell wall morphogenesis
(Antebi and Fink, 1992).
More recently, human SPCA1 was localized to the Golgi
in transfected yeast and Chinese Hamster Ovary cells. Its
capacity to complement the PMR1 null mutation and
restore Ca2þ and Mn2þ transport in yeast was also
demonstrated (Ton et al, 2002). In a recent study, we have
reported functional defects in Ca2þ and/or Mn2þ binding,
phosphorylation, dephosphorylation, or protein expression
in HHD mutants generated by site-directed mutagenesis
(Fairclough et al, 2003). In this study, we provide a wider
understanding of the molecular basis of the disease, by
identifying ATP2C1 mutations in nine unrelated families and
analyzing the effect of a disease-causing point mutation on
hSPCA1 protein function.
Results
Spectrum of mutations The entire coding and flanking
intronic sequence of ATP2C1 was amplified from genomic
DNA by PCR, and screened for mutations by DHPLC, in six
families and three sporadic cases with HHD. Sequencing of
PCR products showing aberrant DHPLC running profiles led
to identification of nine different mutations, five of which
were novel (Table 1).
Nonsense mutations Two different nonsense mutations
resulting in premature termination codons (PTCs) were
identified in this study (Table 1). Family OX25 has a C ! T
transition at nt 457, which results in arginine codon 153
(CGA) being substituted for a stop codon (TGA). A T ! A
transversion at nt 2141 in sporadic case OX29 results in TTA
leucine codon 714 being substituted for a stop codon (TAA).
Insertion/deletion mutations Three deletions were identi-
fied in the coding sequence of ATP2C1, all of which created
a shift in the reading frame and introduced a PTC (Table 1).
Family OX27 has a 1 bp deletion (335delT), resulting in the
introduction of a PTC 19 codons downstream of the
deletion site. Families OX26 and PL1 both have 4 bp
deletions (1089delTCAC and 2374delTTTG), resulting in
introduction of PTCs 21 and 9 codons, respectively,
downstream of the deletion site. A guanine deletion,
together with a large insertion of approximately 24 adenines
followed by a thymine (76delGins  24), was identified in
family NC13. Sequence analysis of eight subclones of this
region from all available affected family members revealed
the number of inserted adenines to vary between 20 and 25,
making the precise consequence of this mutation difficult to
predict.
Splice-site mutations Two mutations were predicted to
affect mRNA splicing, through alteration of the invariant
splice acceptor site consensus sequence GT (Table 1).
Sporadic case NC12 has a G ! A transition in intron 2
(118(1G-A)), whereas a 1 bp thymine insertion (GTT) was
Table 1. ATP2C1 mutations identiﬁed in HHD patients
Patientsa DNA changeb Protein changeb Location Putative protein domainc Veriﬁcation method
Nonsense
OX25 (f ) 457C ! T R153X Exon 7 Actuator AvaI site
OX29 (s ) 2141T ! A L714X Exon 23 M5 Sequencing
Insertions/deletions
NC13 (f ) 76delGins  24 Unknownd Exon 2 N terminal 3% agarose gel
OX27 (f ) 335delT 111LfsX19
e Exon 5 M2 Hpy CH4 IV
OX26 (f ) 1089delTCAC 363TfsX21 Exon 13 Phosphorylation Sequencing
PL1 (f ) 2374delTTTG 791LfsX9 Exon 24 M7 TthIII, sequencing
Splice-site
NC12 (f ) 118(1G ! A) (aberrant splicing) Intron 2 N terminal AluI site
NC11 (f ) 1840(2insT) (aberrant splicing) Intron 19 ATP-binding—hinge NlaIII site
Missense
OX28 (s) 1582G ! C A528P Exon 18 Phosphorylation Sequencing
aThe bracketed letter after the patient name refers to the sporadic (s) or familial (f ) nature of HHD.
bNucleotide and amino acid numbering is based on the cDNA sequence reported by Hu et al (2000), with the adenosine of the initiation codon
assigned position 1.
cPutative protein domain prediction is based on the position of the equivalent residue within the structure of SERCA1a.
dAs the precise number of bases inserted could not be determined by analysis of genomic DNA alone, it is not known whether this mutation creates a
shift in the reading frame or not.
eMutation nomenclature is such that 111LfsX19 indicates a frameshift where Leu111 is the first affected amino acid, followed by a PTC introduced 19
codons downstream.
HHD, Hailey–Hailey disease; PTC, premature termination codon.
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found in intron 19 in family NC11 (1840(2insT)). Unfortu-
nately, in the absence of RNA from the affected patients,
the exact consequence of these mutations could not be
predicted.
Missense mutations A G ! C transversion was identified
at nt 1582 in sporadic case OX28, which resulted in the
amino acid substitution A528P. This mutation was not found
in 50 controls using the verification methods outlined in
Table 1. It occurs at an amino acid residue located in the
putative nucleotide-binding domain of hSPCA1, which is
invariant across a range of SPCA1 orthologues (Fig 1),
suggesting that it may play an important structural/
functional role in the protein.
Consequence of mutation G2582C (A528P) on protein
and mRNA levels To investigate the precise effect on
protein function, site-directed mutagenesis was employed
to introduce mutation G2582C into the previously described
wild-type ATP2C1 mammalian expression clone (Fairclough
et al, 2003). Following over-expression in COS-1 cells, a
rabbit polyclonal antibody, raised against the large cyto-
plasmic domain of hSPCA1 (Fairclough et al, 2003), was
used to compare A528P mutant protein expression and
cellular localization with that of the wild-type, as the
introduction of minor structural abnormalities by the
mutation could lead to mistargeting or protein degradation
(Fig 2). Immunocytochemical staining of wild-type and
A528P-transfected COS-1 cells clearly demonstrated that
the mutant protein is correctly targeted to the Golgi, by co-
localization with the key Golgi marker TGN46 (Fig 2A). But a
comparison of wild type and A528P protein levels, by
western blot analysis of total protein extracted from
transfected COS-1 cells, demonstrated the low expression
of A528P, which was calculated at approximately 30% of
the wild-type protein expression level (Fig 2B, top row).
As previously noted, the immunoreactive band migrated
slightly lower than the predicted Mr of 104 kDa (Fairclough
et al, 2003). The low level of hSPCA1 reactivity in non-
transfected COS-1 cells indicates that the hSPCA1 anti-
serum cross-reacts with the low level of endogenous COS-1
SPCA1 homologue. Equal protein loading was confirmed by
re-staining the membrane for a-tubulin (Fig 2B; middle
row). Lightcycler-based real-time PCR, performed in the
presence of SYBR Green 1, confirmed that the low level
of protein expression observed for A528P was not a result
of a reduced mRNA expression level. ATP2C1 mRNA copy
numbers were calculated to be over 200-fold higher in COS-
1 cells transfected with the wild-type cDNA, compared with
endogenous levels. Mutant ATP2C1 mRNA copy number
did not differ significantly from the wild type (data not
shown). PCR products isolated from the LightCycler
capillaries after cycling are shown in Fig 2C.
Discussion
In this study, we screened the ATP2C1 gene in nine HHD
patients and identified nine different mutations likely to
cause disease. Five of these mutations have not been
previously reported, demonstrating the substantial allelic
heterogeneity of the disease, consistent with findings
reported in other mutation studies. Mutations did not
cluster but were scattered across the length of the ATP2C1
gene. Four of the mutations identified here were previous-
ly described in other studies. The OX25 mutation,
76delGins  24, was previously reported in our earlier study
(NC2, (Sudbrak et al, 2000)). Consistent with their common
geographical origin in northern England, haplotype analysis,
using microsatellite markers flanking ATP2C1, suggested
mutation that 76delGins  24 was inherited from a single
ancestral gene, by revealing a shared disease haplotype in
families OX25 and NC2, (data not shown). Other mutations
identified in this study that have been previously reported
include C457T (JHHD-Su, (Hu et al, 2000); JHHD-1, (Ikeda
et al, 2001); patient 1(Yokota et al, 2002), 1089delTCAC
(OX22, (Dobson-Stone et al, 2002)) and 2374delTTTG (OX7,
(Dobson-Stone et al, 2002); FR5 (Sudbrak et al, 2000); and
HHD-Du and HHD-Ho, (Hu et al, 2000). Unfortunately,
inaccessible DNA made investigations into the recurrent or
sporadic nature of these mutations impossible.
Predicted effects of ATP2C1 mutations on function Six
out of the nine mutations (66%) identified in this study are
Figure 1
Partial amino acid sequence alignment
of hSPCA1 with the Golgi SPCA pumps
from yeast (Pmr1) and rat (SPCA1),
human SERCA2b, and human PMCA2
showing the location and conservative
nature of A528. Identical residues in all
family members are boxed. Those con-
served only in Golgi pumps are shown in
gray. The sequence of part of the large
cytoplasmic domain, encompassing the
phosphorylation and nucleotide-binding
domains, between transmembrane seg-
ments M4 and M5 is shown to highlight the
location of mutation A528P. The position of
the highly conserved phosphorylation site
is also indicated.
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nonsense or frameshift insertion/deletions that lead to
PTCs. The predicted effect of such mutations is an absence
or significant reduction in the level of mutant hSPCA1
protein expression as a consequence of nonsense-
mediated mRNA decay. Alternatively, truncated hSPCA1
proteins could be recognized and targeted for endoplasmic
reticulum-associated degradation by the cell. Nevertheless,
the observation that a high proportion of the ATP2C1
mutations (53%) reported to date lead to PTCs suggests
that haploinsufficiency is a prevalent mechanism for the
dominant inheritance of HHD. The possibility, however, that
some PTCs may lead to truncated proteins that cause
disease through a dominant-negative mechanism cannot
be discounted. In the absence of RNA from affected family
members, it is difficult to predict the effect of the two splice-
site mutations on hSPCA1 protein expression levels. But it
seems highly likely that such mutations will not result in
proteins that function correctly.
Missense mutation A528P was not found in 50 indivi-
duals (100 control chromosomes), suggesting that it does
not represent a benign polymorphism. The functional effect
of mutation A528P, located in the nucleotide-binding pocket
of the large cytosolic domain between transmembrane
segments 4 and 5 of hSPCA1, however, cannot be
predicted a priori. As with the majority of other missense
mutations identified in ATP2C1, A528P occurs at a residue
that is invariant across a range of hSPCA1 orthologues and
paralogues (Fig 1). This high degree of conservation
suggests that the residues involved are essential for correct
protein function. We have recently provided functional
evidence that missense mutations in ATP2C1 affect levels
of hSPCA1 protein expression, or cause lack of ion
transport through specific alterations to the partial reactions
of the catalytic cycle (Fairclough et al, 2003). Analogous to
the conclusions drawn from that study for HHD mutants
L341P, C344Y, C411R, T570I, and G789R, we have now
shown that the low expression level of mutant protein
A528P is not the result of impaired mRNA levels. Instead,
we suggest that the non-conservative change A528P
introduces structural perturbations into hSPCA1. This could
result in either abnormal protein folding or destabilization of
the correctly folded protein, thus making it sensitive to
endoplasmic reticulum-mediated quality control. Such an
effect was previously observed when deletions or specific
substitutions of select residues were made in the N-terminal
region of SERCA1a (Daiho et al, 1999). Although these
mutations had no effect on transcription, translation, or
integration of the protein into the membrane, protein
degradation was shown to be induced at a rate substantially
faster than the wild type. Moreover, detection of some
A528P that had correctly localized to the Golgi in COS-1
cells supports the hypothesis that this amino acid substitu-
tion may induce a more rapid rate of mutant protein
degradation, as it indicates that at least some of the mutant
protein does escape degradation following production in
the endoplasmic reticulum. Nevertheless, by suggesting
that epidermal cells are sensitive to levels of hSPCA1, these
findings further support the theory of haploinsufficiency,
discussed above, as a mechanism for the dominant
inheritance of HHD.
Materials and Methods
Patients Six families and three sporadic cases were included in
this study. All patients were Caucasian and of British origin, with
the exception of one familial case of Polish (PL1) origin. In each
case, HHD was diagnosed by a dermatologist based on family
history, clinical, and histopathological findings. Peripheral blood
samples were taken from patients for DNA isolation in adherence
to the Declaration of Helsinki Guidelines, following their informed
consent and the relevant ethics committee approval for this study.
Mutation and haplotype analysis Genomic DNA was extracted
from peripheral blood leukocytes using standard methods (Sam-
brook et al, 1989). ATP2C1 was amplified from proband and
control DNA by PCR using 28 pairs of oligonucleotide primers
spanning all 28 translated exons together with flanking splice sites
(primer sequences available upon request). Standard reaction
mixes containing 2.5 mM MgCl2 and a 9:1 combination of
Figure 2
A528P protein and mRNA expression in COS-1 cells. (A) Immuno-
cytological staining of COS-1 cells (  100 magnification) transiently
transfected with A528P, wild-type hSPCA1, and empty vector (control).
Cells were incubated with polyclonal antibodies against hSPCA1
(1:1500) and the resident Golgi marker TGN46 (1:300). Secondary
incubation was with FITC-conjugated donkey anti-sheep and goat anti-
rabbit antibodies (1:1000). The superimposable localization of hSPCA1
and TGN46, in a juxtanuclear concentration characteristic of Golgi, is
illustrated by the merged image. (B) Western blot analysis of protein (25
mg) isolated from COS-1 cells transiently transfected with wild-type or
HHD-mutant A528P and empty vector (control). Antibodies used for
incubations included: primary, anti-hSPCA1 (1:500); and secondary,
alkaline phosphatase-conjugated goat anti-rabbit (1:8000). The size of
the protein bands is indicated to the right of the image. The blot was
then stripped and immunostained with mouse anti-a-tubulin (1:2000)
followed by anti-mouse secondary antibody as above. A fluoroimager
model STORM 840 (Molecular Dynamics) was used for blot analysis.
(C) Products generated by Lightcycler-based real-time PCR with
ATP2C1 primers C7F and C7R were isolated and visualized after
electrophoresis on 1.5% agarose gels. Control samples, where no
reverse transcriptase was added (RT enz), were included in all
experiments to control for DNA contamination. Negative controls were
also included during reverse transcription (RT ve) and PCR (PCR
ve). Results represent those obtained from three closely similar
independent experiments.
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AmpliTaq Gold (Perkin-Elmer Life Sciences, Boston, Massachu-
setts) and Pfu Turbo (Stratagene, Amsterdam, the Netherlands)
polymerases were used for PCR. Cycling conditions consisted of
14 touch-down cycles followed by 25 amplification cycles, using
annealing temperatures of 54–581C, as described previously
(Bitoun et al, 2002). PCR amplification was checked by 2.5%
agarose gel electrophoresis. Denaturing high-performance liquid
chromatography (DHPLC) mutation analysis was essentially per-
formed as described before (Dobson-Stone et al, 2000). Proband
samples showing abnormal DHPLC running profiles, in comparison
with controls, were sequenced as previously described (Bitoun
et al, 2002). The presence of each mutation was later confirmed in
all available family members by sequencing or restriction digestion.
Site-speciﬁc mutagenesis and analysis of protein and mRNA
expression Mutation G1582C was introduced into the sequence
of the previously described full-length ATP2C1d cDNA cloned into
mammalian expression vector pMT2, using the Quikchange XL
Site-Directed Mutagenesis Kit (Stratagene) as described in detail in
an earlier study (Fairclough et al, 2003). Transient expression of the
subsequent mutant protein A528P in COS-1 cells, immunostaining,
RNA preparation, and Lightcycler-based real-time PCR analyses
(Roche Applied Science, E. Sussex, UK) were also performed
using previously described methods (Fairclough et al, 2003).
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Appendix: Electronic Database Information Accession
numbers and URLs for data in this article are as follows:
GenBank at The National Centre for Biotechnology
Information (NCBI), http://www.ncbi.nlm.nih.gov/ (GenBank
accession no. AY268375 for ATP2C1d/hSPCA1d and
CA942187 for GAPDH).
Online Mendelian Inheritance in Man (OMIM), http://www.
ncbi.nlm.nih.gov/Omim (for Hailey–Hailey Disease 16960).
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